*Corresponding author:
Teruo Inoue, Department of Cardiovascular Medicine, Japan and Satoko Kishimoto, Research Support Center, Center for Regenerative Medicine Tochigi, JapanbReceived: December 12, 2018; Published: December 21, 2018
DOI: 10.26717/BJSTR.2018.12.002509
To view the Full Article Peer-reviewed Article PDF
Background: Low molecular weight heparin/protamine micro/nanoparticles (LH/P-MPs) has been shown as cell carriers for adipose-derived regenerative cells (ADRCs) to augment cell viability, leading to accelerating angiogenesis in mouse limb ischemia models, compared to ADRCs alone.
Material & Methods: Human ADRCs were isolated from 3 patients with critical limb ischemia and incubated with and without LH/P-MPs Incubation of ADRCs with LH/P-MPs produced cell aggregation (ADRC/LH/P-MPs aggregates). Serial changes in survived ADRCs were compared between ADRC/LH/P-MPs aggregates and ADRCs alone.
Results: Patients’ derived ADRCs promptly decreased cell number in suspension culture, eventually they were eliminated through cell death after seven days. ADRC/LH/P-MPs aggregates remarkably slowed down the cell death.
Conclusion: The LH/P-MPs could enhance the viability of human ADRCs. The LH/P-MPs could be a promising option in ADRCs-based therapeutic angiogenesis in patients with critical limb ischemia.
Keywords :Limb Ischemia; Adipose-Derived Regenerative Cells; Low Molecular Weight Heparin/Protamine Micro/Nanoparticles; Angiogenesis Therapy; Human
Introduction| Materials and Methods| Results| Discussion| References|